FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075342258> ?p ?o ?g. }

• W2075342258 endingPage "NA" @default.
• W2075342258 startingPage "NA" @default.
• W2075342258 abstract "Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy-naïve patients with nonsquamous nonsmall-cell lung cancer (NSCLC). However, the effects of combining bevacizumab with other standard, front-line, platinum-based doublets have not been extensively explored. We designed this single treatment arm, phase 2 trial to determine whether the combination of carboplatin, docetaxel, and bevacizumab is tolerable and prolongs progression-free survival of chemotherapy-naïve patients with advanced, nonsquamous NSCLC.Forty patients were treated with up to 6 cycles of carboplatin (AUC 6), docetaxel (75 mg/m(2)), and bevacizumab (15 mg/kg) on Day 1 every 21 days. Patients with an objective response or stable disease received maintenance bevacizumab (15 mg/kg) every 21 days until disease progression. The primary endpoint was median progression-free survival. Secondary endpoints included safety, response rates, and overall survival.The median number of chemotherapy and maintenance bevacizumab cycles/patient was 6 and 2, respectively. Grades 3-5 adverse events included febrile granulocytopenia (10%), infections (13%), bleeding (13%), thrombotic events (13%), hypertension (5%), bowel perforation (5%), and proteinuria (3%). Median progression-free survival was 7.9 months and median overall survival was 16.5 months. Partial responses were observed in 21 patients (53%), and stable disease >or=6 weeks occurred in another 17 patients (43%), for a disease control rate of 95%.Carboplatin, docetaxel, and bevacizumab were feasible and effective for front-line treatment of advanced, nonsquamous NSCLC. These data provide further evidence that bevacizumab may be used in combination with multiple standard, platinum-based doublets in this setting." @default.
• W2075342258 created "2016-06-24" @default.
• W2075342258 creator A5009466654 @default.
• W2075342258 creator A5017187936 @default.
• W2075342258 creator A5023699305 @default.
• W2075342258 creator A5038682299 @default.
• W2075342258 creator A5041570474 @default.
• W2075342258 creator A5048478992 @default.
• W2075342258 creator A5067386747 @default.
• W2075342258 creator A5069190968 @default.
• W2075342258 creator A5080439835 @default.
• W2075342258 creator A5085188591 @default.
• W2075342258 date "2010-01-01" @default.
• W2075342258 modified "2023-10-18" @default.
• W2075342258 title "Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer" @default.
• W2075342258 cites W1615780386 @default.
• W2075342258 cites W1918989451 @default.
• W2075342258 cites W1935885922 @default.
• W2075342258 cites W1967040948 @default.
• W2075342258 cites W1973498312 @default.
• W2075342258 cites W1980212074 @default.
• W2075342258 cites W2000626895 @default.
• W2075342258 cites W2037139573 @default.
• W2075342258 cites W2085527076 @default.
• W2075342258 cites W2087911316 @default.
• W2075342258 cites W2093091112 @default.
• W2075342258 cites W2118411779 @default.
• W2075342258 cites W2127405377 @default.
• W2075342258 cites W2130334661 @default.
• W2075342258 cites W2133898439 @default.
• W2075342258 cites W2139240866 @default.
• W2075342258 cites W2139248078 @default.
• W2075342258 cites W2139675556 @default.
• W2075342258 cites W2144660856 @default.
• W2075342258 cites W2145835533 @default.
• W2075342258 cites W2166399931 @default.
• W2075342258 cites W2205783247 @default.
• W2075342258 cites W2247183672 @default.
• W2075342258 cites W2302208907 @default.
• W2075342258 cites W2535315677 @default.
• W2075342258 cites W4239851482 @default.
• W2075342258 doi "https://doi.org/10.1002/cncr.24996" @default.
• W2075342258 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5145307" @default.
• W2075342258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20225327" @default.
• W2075342258 hasPublicationYear "2010" @default.
• W2075342258 type Work @default.
• W2075342258 sameAs 2075342258 @default.
• W2075342258 citedByCount "8" @default.
• W2075342258 countsByYear W20753422582012 @default.
• W2075342258 countsByYear W20753422582013 @default.
• W2075342258 countsByYear W20753422582015 @default.
• W2075342258 crossrefType "journal-article" @default.
• W2075342258 hasAuthorship W2075342258A5009466654 @default.
• W2075342258 hasAuthorship W2075342258A5017187936 @default.
• W2075342258 hasAuthorship W2075342258A5023699305 @default.
• W2075342258 hasAuthorship W2075342258A5038682299 @default.
• W2075342258 hasAuthorship W2075342258A5041570474 @default.
• W2075342258 hasAuthorship W2075342258A5048478992 @default.
• W2075342258 hasAuthorship W2075342258A5067386747 @default.
• W2075342258 hasAuthorship W2075342258A5069190968 @default.
• W2075342258 hasAuthorship W2075342258A5080439835 @default.
• W2075342258 hasAuthorship W2075342258A5085188591 @default.
• W2075342258 hasBestOaLocation W20753422581 @default.
• W2075342258 hasConcept C126322002 @default.
• W2075342258 hasConcept C141071460 @default.
• W2075342258 hasConcept C143998085 @default.
• W2075342258 hasConcept C203092338 @default.
• W2075342258 hasConcept C2776256026 @default.
• W2075342258 hasConcept C2776694085 @default.
• W2075342258 hasConcept C2777802072 @default.
• W2075342258 hasConcept C2778239845 @default.
• W2075342258 hasConcept C2781190966 @default.
• W2075342258 hasConcept C2781451048 @default.
• W2075342258 hasConcept C31760486 @default.
• W2075342258 hasConcept C535046627 @default.
• W2075342258 hasConcept C71924100 @default.
• W2075342258 hasConceptScore W2075342258C126322002 @default.
• W2075342258 hasConceptScore W2075342258C141071460 @default.
• W2075342258 hasConceptScore W2075342258C143998085 @default.
• W2075342258 hasConceptScore W2075342258C203092338 @default.
• W2075342258 hasConceptScore W2075342258C2776256026 @default.
• W2075342258 hasConceptScore W2075342258C2776694085 @default.
• W2075342258 hasConceptScore W2075342258C2777802072 @default.
• W2075342258 hasConceptScore W2075342258C2778239845 @default.
• W2075342258 hasConceptScore W2075342258C2781190966 @default.
• W2075342258 hasConceptScore W2075342258C2781451048 @default.
• W2075342258 hasConceptScore W2075342258C31760486 @default.
• W2075342258 hasConceptScore W2075342258C535046627 @default.
• W2075342258 hasConceptScore W2075342258C71924100 @default.
• W2075342258 hasLocation W20753422581 @default.
• W2075342258 hasLocation W20753422582 @default.
• W2075342258 hasLocation W20753422583 @default.
• W2075342258 hasLocation W20753422584 @default.
• W2075342258 hasOpenAccess W2075342258 @default.
• W2075342258 hasPrimaryLocation W20753422581 @default.
• W2075342258 hasRelatedWork W1983576003 @default.
• W2075342258 hasRelatedWork W1997961771 @default.
• W2075342258 hasRelatedWork W2027569686 @default.

• next